Consumers in NSW still face “ludicrous” and “expensive” barriers to accessing medicinal ecstasy despite the approved use of MDMA and other psychedelics for mental health conditions in Australia, according to a minister.
In 2023, Australia’s Therapeutic Goods Administration (TGA) approved the use of MDMA for treating post-traumatic stress disorder and treatment-resistant depression.